Home
Markets
Charts & Ideas
Algo
News
Store
Brokers
Download
Economic Calendar
Trading Signals
WebTerminal
Heatmap
Type
/
to search: @user, $symbol
Search
Log in
Create an account
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
XLO
#4248
Xilio Therapeutics, Inc. - Common Stock
9.0
0
USD
+0.01%
Market Price
Sector:
Healthcare
Base:
USD
Profit Currency:
USD
Daily Range
Year Range
Daily Change
+0.90%
Monthly Change
+0.45%
6 month change
+1630.77%
Year Change
+1204.35%
Previous Close
8.9
2
Open
9.0
0
Low
9.0
0
High
9.0
0
Volume
1
Markets
US Stock Market
Healthcare
Biotechnology
XLO
1D
1W
1M
3M
6M
YTD
1Y
5Y
Open full chart
Financials
Overview
Statement
Statistics
Documents
2024
Quarterly report, Q2 FY2024
2024.08.08
Xilio Therapeutics, Inc. quarterly report, Q2 FY2024
10-Q
Current report, Q2 FY2024
2024.06.13
Xilio Therapeutics, Inc. current report, Q2 FY2024
8-K
Current report, Q2 FY2024
2024.06.17
Xilio Therapeutics, Inc. current report, Q2 FY2024
8-K
1
2
3
4
5
News
Cancer Stocks That Are Advancing the Future of Oncology Care
Xilio Therapeutics, Inc. (XLO) Reports Q1 Loss, Beats Revenue Estimates
Opus Genetics, Inc. (IRD) Reports Q1 Loss, Misses Revenue Estimates
Oculis Holding AG (OCS) Reports Q1 Loss, Lags Revenue Estimates
Xilio Therapeutics (XLO) Upgraded to Buy: What Does It Mean for the Stock?
Xilio Therapeutics (XLO) Upgraded to Buy: What Does It Mean for the Stock?
Cancer Stocks to Buy as Innovation Reshapes Global Oncology Market
Xilio Therapeutics implements 1-for-14 reverse stock split
Xilio Therapeutics secures $35.8 million from warrant exercises
Xilio Development earnings missed by $0.06, revenue topped estimates
Xilio Therapeutics, Inc. (XLO) Reports Q3 Loss, Misses Revenue Estimates
BioXcel Therapeutics, Inc. (BTAI) Reports Q3 Loss, Misses Revenue Estimates